EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effects of adjunctive memantine on executive function and global cognition in bipolar disorder (BD): A randomized, double-blind, placebo-controlled clinical trial

Hasan Mirzazadeh, Erfan Sadeghi, Sara Mostafavi, Saghar Elmi, Reza Moshfeghinia, Somayyeh Rahimi

Journal of Affective Disorders · 2026-12 · 414 · 122309

DOI: 10.1016/j.jad.2026.122309 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2026-12. Verfasst von Hasan Mirzazadeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Psychiatry and Behavior Science, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Memantine, Executive Function, Bipolar Disorder, Cognition. Die Arbeit nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cognitive impairment contributes substantially to disability in bipolar disorder (BD), but effective pharmacologic options remain limited. This trial evaluated whether adjunctive memantine improves global cognition and executive function in BD. METHODS: In this double-blind, placebo-controlled randomized trial, patients with bipolar I disorder (B1D) receiving lithium and olanzapine were assigned to memantine or placebo. Memantine was titrated to 20 mg/day over 6 weeks. Cognitive outcomes were assessed at baseline, week 6, and week 18. Global cognition was measured with the Neurocognitive Assessment Battery (NuCog), and executive function with the Frontal Assessment Battery (FAB). Data were analyzed using generalized estimating equations and Bonferroni-adjusted post-hoc tests. RESULTS: Sixty-three participants were randomized (memantine, n = 31; placebo, n = 32), and all completed follow-up. Groups were comparable at baseline for demographic and clinical variables and for most cognitive measures. Both groups improved over time (P < 0.001), but improvement was greater with memantine for global cognition at week 6 (MD = 9.32; 95% CI, 4.84-13.81; P < 0.001) and week 18 (MD = 12.69; 95% CI, 8.67-16.71; P < 0.001). FAB total scores favored memantine at week 18 (MD = 2.68; 95% CI, 1.76-3.61; P < 0.001), but not at week 6. Domain analyses showed significant benefits for NuCog attention, visuoconstructional ability, memory, and executive function, and for several FAB subscales by week 18. CONCLUSIONS: Adjunctive memantine improved global cognition and, over longer follow-up, executive function in BD. These findings support NMDA receptor modulation as a potential strategy for cognitive dysfunction in BD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MemantineExecutive FunctionBipolar DisorderCognitionHumansDouble-Blind MethodFemaleMaleAdultDrug Therapy, CombinationMiddle AgedCognitive EnhancementOlanzapineNeuropsychological TestsTreatment OutcomeAntipsychotic Agents

Stichwörter der Autor:innen

Cognitive impairmentDipolar I disorderExecutive functionMemantineNMDA receptorRandomized controlled trial

Substanzen

MemantineOlanzapineAntipsychotic Agents

Autor:innen und Institutionen

  • Research Center for Psychiatry and Behavior Science, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Non-Communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran; Student Research Committee, Qom University of Medical Sciences, Qom, Iran.
  • Research Center for Psychiatry and Behavior Science, Shiraz University of Medical Sciences, Shiraz, Iran; Clinical Research Development Center, Amir Oncology Teaching Hospital, Shiraz University of Medical Sciences, Shi…
  • Research Center for Psychiatry and Behavior Science, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: Somayyehrahimi@sums.ac.ir.

Zitieren

APA

Mirzazadeh, H., Sadeghi, E., Mostafavi, S., Elmi, S., Moshfeghinia, R., & Rahimi, S. (2026). Effects of adjunctive memantine on executive function and global cognition in bipolar disorder (BD): A randomized, double-blind, placebo-controlled clinical trial. Journal of Affective Disorders, 414, 122309. https://doi.org/10.1016/j.jad.2026.122309

Vancouver

Mirzazadeh H, Sadeghi E, Mostafavi S, Elmi S, Moshfeghinia R, Rahimi S. Effects of adjunctive memantine on executive function and global cognition in bipolar disorder (BD): A randomized, double-blind, placebo-controlled clinical trial. Journal of Affective Disorders. 2026;414:122309. doi:10.1016/j.jad.2026.122309

BibTeX
@article{Mirzazadeh2026,
  author = {Mirzazadeh, Hasan and Sadeghi, Erfan and Mostafavi, Sara and Elmi, Saghar and Moshfeghinia, Reza and Rahimi, Somayyeh},
  title = {Effects of adjunctive memantine on executive function and global cognition in bipolar disorder (BD): A randomized, double-blind, placebo-controlled clinical trial},
  journal = {Journal of Affective Disorders},
  year = {2026},
  volume = {414},
  pages = {122309},
  doi = {10.1016/j.jad.2026.122309}
}
Kostenlos starten →